Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents

Appendix C: Panel Roster and Financial Disclosures


Last Updated: February 1, 2016; Last Reviewed: February 1, 2016

Member Financial Disclosure
Company Relationship
Casper, Corey University of Washington School of Medicine Centocor Research Support
GlaxoSmithKline Scientific Advisory Board
Janssen Pharmaceuticals Consultant, Research Support
Johnson & Johnson Research Support
Sanofi Pasteur Research Support
Temptime Scientific Advisory Board
Durand, Christine Johns Hopkins University Gilead Advisory Board, Research Support
Gnann, John Medical University of South Carolina BioCryst DSMB Member
GlaxoSmithKline DSMB Member
Merck DSMB Member, Consultant
Jabs, Douglas Ichan School of Medicine at Mount Siani None N/A
Jacobson, Mark University of California San Francisco None  N/A
Johnston, Christine* University of Washington Agenus Research Support
Aicuris Research Support
Genocea Research Support
Gilead Research Support
Vical Research Support
Kimberlin, David University of Alabama at Birmingham Alios Research Support
GlaxoSmithKline Research Support
Parsons, Christopher Louisiana State University School of Medicine in New Orleans None N/A
Phipps, Warren University of Washington School of Medicine None N/A
Wald, Anna University of Washington School of Medicine Agenus Research Support
AiCuris Consultant
Amgen Consultant
Eisai Consultant
Genocea Research Support
Gilead Research Support
Merck DSMB Member
Up-To-Date Other
Vical Research Support
* Group lead

Note: Members were asked to disclose all relationships from 24 months prior to the updated date. The period of reporting was from February 1, 2014, through February 1, 2016.

Download Guidelines